Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2021 Financial Results on August 5, 2021
Vir Biotechnology (Nasdaq: VIR) announced it will provide a corporate update along with its financial results for Q2 2021 on August 5, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Vir Biotechnology (Nasdaq: VIR) announced it will provide a corporate update along with its financial results for Q2 2021 on August 5, 2021. The press release will be accessible after market close on their website. Vir focuses on combining immunologic insights with advanced technologies to combat serious infectious diseases, with a development pipeline that includes candidates targeting COVID-19, hepatitis B, influenza A, and HIV.
Positive
- Scheduled corporate update and Q2 2021 financial results on August 5, 2021.
- Development pipeline includes multiple candidates targeting significant infectious diseases.
Negative
- None.
Details
News Market Reaction – VIR
The recorded move for VIR in the trading session of this news was -1.23%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, July 22, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the second quarter ended June 30, 2021 on Thursday, August 5, 2021.
The update will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio.
About Vir Biotechnology
Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B virus, influenza A and human immunodeficiency virus. For more information, please visit www.vir.bio.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.